PetVivo raises $5M in Series B convertible preferred stock financing

PetVivo Holdings, Inc.

Initial $600K received; investor may purchase remaining $4.4M by May 27, 2025.
Preferred shares pay 10% annual dividend in common stock; convertible 1:1 into common.
Company can call shares after 2 years at $1.15 per share; proceeds for commercialization.
Stock trades OTCQB (PETV) after Nasdaq delisting; offering is exempt under Section 4(a)(2).
Use of proceeds: lead products Spryng and PrecisePRP, clinical trials, working capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.